Nifurtimox (1 brand name, 1 dosage form, 1 route)
Available dosage forms: TABLET.
Routes of administration: ORAL.
Brand Names
- LAMPIT
Indications and Usage
LAMPIT is indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi [see Clinical Studies (14)].
Contraindications
LAMPIT tablets are contraindicated in: •Patients with known hypersensitivity to nifurtimox or any of the excipients in LAMPIT [see Warnings and Precautions (5.4)]. •Patients who consume alcohol during treatment [see Drug Interactions (7)]
Adverse Reactions
The following serious or otherwise important adverse reactions are discussed elsewhere in the labeling: •Potential for Genotoxicity, Carcinogenicity, and Mutagenicity [see Warnings and Precautions (5.1)] •Worsening of Neurological and Psychiatric Conditions [see Warnings and Precautions (5.3)] •Hypersensitivity [see Warnings and Precautions (5.4)] •Decreased Appetite and Weight Loss [see Warnings and Precautions (5.5)] •Porphyria [see Warnings and Precautions (5.6)]
Drug Interactions
Concomitant use of LAMPIT with alcohol may increase the incidence and severity of undesirable effects similar to other nitrofurans and nitroheterocyclic compounds. LAMPIT is contraindicated in patients who consume alcohol during treatment [see Dosage and Administration (2.2) Contraindications (4)].
Mechanism of Action
Nifurtimox is an antiprotozoal drug [see Microbiology (12.4)].